SavedAdd your journal

Journals / Journal of Experimental and Clinical Medicine / 2021 / Cilt: 38 - Sayı: 4

Is There Any Possibility of Uterine Sarcoma, STUMP and Benign Myoma Variants in the Patients Operated for Myoma Uteri

Elif TOPCU
Volkan ÜLKER
Nermin GUNDUZ
Hale GÖKSEVER ÇELİK
Pages
538–544
Publication Date
2021-10-09
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the preoperative evaluation, it is necessary to pay attention to the patients’ characteristics, to evaluate the risk factors for the possibility of a malignancy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Malignant pathologies may be observed in the histopathological examination of the patients who were operated with the diagnosis of myoma uteri.
📊
Key Findings & Data:We aimed to to investigate the rates of detection of uterine sarcoma, smooth muscle tumor of uncertain malignant potential and benign myoma variants who were operated due to myoma uteri.
💡
Conclusion & Impact:In the preoperative evaluation, it is necessary to pay attention to the patients’ characteristics, to evaluate the risk factors for the possibility of a malignancy.
🔬Design:Research Article
📍Scope:2012-2018 Verileri
⚙️Variables:hysterectomy · myoma uteri · uterine sarcoma

Abstract

Malignant pathologies may be observed in the histopathological examination of the patients who were operated with the diagnosis of myoma uteri. We aimed to to investigate the rates of detection of uterine sarcoma, smooth muscle tumor of uncertain malignant potential and benign myoma variants who were operated due to myoma uteri. Patients who were operated with the diagnosis of myoma uteri between 2012-2018 were included. Patients with and without malignant pathology were compared in terms of their characteristics. The malignancy was encountered in 39 patients (1.5%) among 2583 patients. A significant difference was found between the patients with and without malignancy in terms of age, admission complaints, and cervical smear results. Patients in the malignant group were found to be older (52.5±11.0 vs 48.1±6.1, p=0.016). Postmenopausal bleeding was significantly a more common complaint in the malignant group (p=0.028). The rate of abnormal cytology in the cervical smear results in the malignant group was 5.1% (p=0.004). Pathology reports of the patients who were operated for myoma uteri may result with malignancy. In the preoperative evaluation, it is necessary to pay attention to the patients’ characteristics, to evaluate the risk factors for the possibility of a malignancy.

🔖

Cite This Article

TOPCU, E., ÜLKER, V., GUNDUZ, N., ÇELİK, H. G. (2021). Is There Any Possibility of Uterine Sarcoma, STUMP and Benign Myoma Variants in the Patients Operated for Myoma Uteri. Journal of Experimental and Clinical Medicine, Cilt: 38 - Sayı: 4, 538–544. https://ajindex.com/articles/677858

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Augusto KL, Brilhante AVM, Modesto GCD, Saboia DM, Rocha CFC, Karbage SAL, et al. Costs and mortality rates of surgical approaches to hysterectomy in Brazil. Rev Saude Publica 2018; 52: 25
  2. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100
  3. Berisavac M, Sparic R, Argirovic R. Contraception: modern trends and controversies. Srp Arh Celok Lek. 2009;137(5-6):310–319
  4. Christacos NC, Quade BJ, Dal Cin P, Morton CC. Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 2006; 45:304
  5. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94(4):435–438
  6. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010; 116:131–139
  7. Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004; 92:648
  8. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician. 2007;75(10):1503–1508
  9. Felix AS, Cook LS, Gaudet MM, Rohan TE, Schouten LJ, Setiawan VW, et al. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer. 2013;108(3):727–734
  10. Fleischer R, Weston GC, Vollenhoven BJ, Rogers PA. Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):603–614
  11. He Y, Zeng Q, Li X, Liu B, Wang P. The association between subclinical atherosclerosis and uterine fibroids. PLoS One. 2013;8(2):e57089–e57089
  12. Hodge JC, Morton CC. Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet 2007; 16 Spec No 1:R7
  13. Hodge JC, Pearce KE, Clayton AC, Taran FA, Stewart EA. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol 2014; 210:572.e1
  14. Jin Y, Pan L, Wang X, Dai Z, Huang H, Guo L, et al. Clinical characteristics of endometrial stromal sarcoma from an academic medical hospital in China. Int J Gynecol Cancer 2010; 20:1535
  15. Kapp D S, Shin J Y, Chan J K. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Canc